A Complete Guide to AAV Gene Therapy: From Virology, Gene Delivery to Clinical Success and Safety Challenges
- Jason Lu
- Jul 25
- 29 min read
Updated: 2 days ago
Executive Summary
If you only have three minutes to read this article, I hope you'll remember these six things first.
The real challenge of Gene Therapy is not just finding the therapeutic gene, but how to safely and effectively deliver the gene into the right cells.
AAV (Adeno-associated virus) is one of the most mature in vivo gene delivery platforms currently available. Researchers remove most of the virus's genes, retaining only the structures needed for delivery, and then insert the DNA for therapeutic purposes.
The advantage of AAV is that it can maintain gene expression for a longer period of time in many inactive dividing cells, and recombinant AAV mainly exists in the form of episomal DNA. However, "major non-integration" does not mean that low-frequency genomic integration is completely impossible.
AAV also has clear limitations. Its load is usually only about 4.7 kb, patients may already have neutralizing antibodies, and it is usually difficult to use the same or similar capsid again after treatment.
The risks of high-dose, systemic AAV therapy should not be confused with those of low-dose, locally administered AAV. Hepatotoxicity, complement activation, thrombocytopenia, immune myositis, and some neurotoxicities are all issues that must be managed in clinical development.
The next generation of Gene Therapy will not only include AAV. AAV, LNP, Lentivirus, Virus-like Particle (VLP), and other delivery platforms will complement each other based on disease, target organ, and treatment mechanism.
Foreword: Why do I want to reintroduce AAV Gene Therapy?
In recent years, whenever Gene Therapy is discussed, AAV is almost always mentioned.
From Luxturna for treating hereditary retinopathy and Zolgensma for treating spinal muscular atrophy, to Hemgenix and Roctavian gene therapies for hemophilia, and the highly anticipated Duchenne muscular dystrophy therapy for Elevidys, adeno-associated virus (AAVs) have gradually evolved from laboratory research tools into a treatment platform capable of truly altering the natural course of diseases. The FDA currently lists several AAV-based therapies among its approved cell and gene therapy products. ( US Food and Drug Administration )
But every time I chat with students, friends, or even investors, I find that they often have two completely different questions about AAV.
People without a biology background often ask:
Viruses make people sick, so why are we now trying to inject them into the human body?
Those already working in gene therapy or drug development may be more concerned with:
What factors determine tissue tropism in AAV?
Why can the same capsid with a different expression cassette result in completely different toxicities and effects?
Why does AAV, which looks so simple in the laboratory, become so expensive and complicated in GMP manufacturing?
Therefore, this article will be divided into two parts.
The first half starts with DNA, proteins, viruses, and gene delivery, allowing even those without a scientific background to gradually understand why AAV can be used to treat diseases.
The second half will further discuss AAV genome, capsid biology, tissue tropism, expression cassette, manufacturing, quality control, clinical safety, and next-generation vector engineering.
I hope this is not just an explanation of AAV terms, but a complete guide that allows readers from different backgrounds to enter the world of Gene Therapy from the same entry point.
Reading Guide
Part I｜Fundamental Science
Suitable for readers who are new to Gene Therapy.
You will learn:
The relationship between DNA, RNA, and protein
Why do genetic diseases occur?
What exactly does Gene Therapy treat?
Why is delivery the biggest challenge?
How viruses are modified into treatment tools
What are the differences between AAV and other common pathogenic viruses?
Part II｜Advanced AAV Biology and Development
Suitable for life science graduate students, biotechnology researchers, and Gene Therapy and AAV scientists.
The content includes:
AAV genome and recombinant vector design
Capsid structure, serotype and tissue tropism
Promoter, transgene and regulatory element
AAV payload limitation
Manufacturing, purification and quality control
Clinical products and safety
Elevidys Case Study
Next-generation AAV engineering
Positioning of AAV, LNP, and other delivery platforms
Part I | Fundamental Science: An Introduction to Gene Therapy for Readers Without a Science Background
The human body is actually a protein factory.
When many people first hear about Gene Therapy, they instinctively think it's about "modifying human genes".
However, most commercially available AAV gene replacement therapies do not primarily aim to redesign a person's genome, but rather to provide a working gene that allows specific cells to reproduce the protein that the patient lacks.
Human cells produce large amounts of protein every day.
Proteins aren't just found in fitness supplements. Most of the molecules that actually perform functions in the human body are essentially proteins.
For example:
Insulin helps regulate blood sugar.
Factor VIII and Factor IX are involved in the coagulation reaction.
Dystrophin helps muscle cells withstand the mechanical stress generated during contraction.
SMN protein is crucial for the survival and normal function of motor neurons.
RPE65 participates in the visual cycle of the retina.
If a gene mutates and is unable to produce enough functional protein, cell function may gradually become problematic.
This is also the starting point for many single-gene diseases.
DNA is like the human body's instruction manual, but the manual itself isn't responsible for the work.
I often use recipes to explain DNA.
If you have a cake recipe, the correct content should be:
200 grams of flour.
However, due to a printing error, it became:
20 grams of flour.
No matter how hard a chef tries, if they keep following the wrong recipe, the cake they make will hardly turn out right.
The same applies to the human body.
DNA stores the instructions for making molecules; RNA transmits some of those instructions; and proteins are the products that are made according to those instructions and actually perform their functions.
This information flow is often simplified to:
DNA → RNA → Protein
This is what is commonly referred to as Central Dogma in molecular biology.
The concept of gene replacement therapy is to deliver a normally functioning DNA into a cell, allowing the cell to begin producing the protein that the patient is lacking.
What are the differences between Gene Therapy, mRNA Therapy, and Gene Editing?
These three nouns often appear together, but they are not the same thing.
Gene replacement therapy
Provide a functional gene that allows cells to produce therapeutic proteins.
Most AAV gene therapy falls into this category.
It typically does not require removing the patient's original mutated gene, but rather provides an additional working gene expression cassette.
mRNA therapy
The mRNA is delivered directly into the cytoplasm, allowing the cell to produce proteins over a period of time.
Because mRNA usually degrades gradually, its expression time is relatively short, but this also makes it easier to control and allows for repeated administration.
Gene editing
Tools such as CRISPR-Cas, base editor, or prime editor can be used to directly modify the DNA in cells.
It can remove, modify, or shut down specific genes, but at the same time, it requires very precise control over delivery, editing efficiency, and off-target risk.
Simply put:
Gene replacement means "to provide a correct instruction manual".
mRNA therapy is "directly providing a working instruction for temporary use".
Gene editing means "modifying the original instruction manual".
Real-life disease case: What exactly should Gene Therapy supplement?
Spinal Muscular Atrophy
Spinal muscular atrophy, or SMA for short, is a serious hereditary neuromuscular disease.
Patients typically lack the SMN1 gene, which is essential for normal function, resulting in insufficient survival motor neuron protein and a gradual loss of motor neuron function.
Zolgensma uses an AAV9-based vector to deliver a functional SMN1 transgene to treat SMA children under two years of age with bis-allelic SMN1 mutations. ( US Food and Drug Administration )
This example is important because it shows that Gene Therapy's goal is not to revive dead neurons, but to provide the missing proteins as early as possible to reduce irreversible damage caused by the continued progression of the disease.
Hemophilia B
Hemophilia B patients lack or are unable to produce Factor IX normally.
Traditional treatments typically require long-term supplementation of clotting factors. The idea behind AAV gene therapy is to deliver the Factor IX gene into liver cells, turning the patient's own liver into a "factory" for clotting factors.
Hemgenix is an AAV5-based gene therapy for specific adult patients with Hemophilia B. Its goal is to reduce the frequency of bleeding and the need for Factor IX replacement therapy. ( US Food and Drug Administration )
Hereditary retinal diseases
Luxturna is used for patients with confirmed biased RPE65 mutation-associated retinal dystrophy who still possess viable retinal cells. Treatment is not administered via systemic intravenous injection, but rather through local ophthalmic surgery to deliver a vector to the relevant area of the retina. ( US Food and Drug Administration )
This also illustrates something very important:
The efficacy and risks of gene therapy are determined not only by the vector, but also by the administration site, dosage, target cells, and disease progression.
The most difficult problem for Gene Therapy is actually delivery.
When scientists find the genes that cause the disease, the treatment problem is not automatically solved.
DNA is a large, negatively charged molecule.
The cell is surrounded by a cell membrane, and inside the cell are multiple barriers such as endosomes, cytosols, and nuclear membranes. Even if DNA successfully enters the cell, it does not mean that it can successfully reach the cell nucleus, remain stable, and exert its effects at the correct time and dosage.
A successful gene delivery system must accomplish at least the following:
Maintain sufficient stability within the body.
To reach the organ that needs treatment.
Enter the correct cell.
Avoid degradation in endosomes.
Deliver the genetic cargo to the correct cellular region.
To produce sufficient protein expression.
It does not cause unacceptable immune or toxic reactions.
Therefore, finding the disease gene is only the first step.
The key to Gene Therapy's success lies in whether the therapeutic cargo can be delivered to the right place.
What are some examples of Gene Delivery Platforms?
The commonly used methods can be roughly divided into three categories.
Physical delivery
For example, electroneutration, microinjection, or other physical methods.
These technologies can temporarily alter cell membrane permeability, allowing DNA, RNA, or protein to enter the cell.
They are very useful in ex vivo cell engineering, for example, by first taking cells out of the body, performing genetic manipulations, and then reinfusing them into the patient.
However, it is usually impractical to directly electroporate a large number of cells dispersed in different organs within the human body.
Non-viral delivery
The most representative example is the Lipid Nanoparticle, also known as LNP.
LNPs have been proven to be effective in delivering mRNA and siRNA, and are currently being widely studied for use in CRISPR components and other nucleic acid cargoes.
Its advantages include:
No need to use viral protein shell
The manufacturing process is relatively modular.
It can deliver larger or different forms of nucleic acid.
Some applications have the potential for repeated drug administration.
However, most current systems are still highly biased towards the liver. How to accurately deliver the technology to other organs and specific cells is an important research direction for the next generation of LNPs.
Viral delivery
Viruses have evolved over a long period of time and are very adept at finding cells, entering cells, and transmitting genetic material.
What Gene Therapy does is remove the genes that viruses originally use to replicate and cause disease, and then put them into a therapeutic genetic cargo.
The virus was thus transformed from a pathogen into an engineered delivery vehicle.
Why are viruses natural gene delivery machines?
Imagine the human body as a city, and cells as buildings.
The virus is like a delivery system that knows the city's roads well.
It must be completed:
Identify the location: Locate the receptor or attachment factor on the cell surface.
Entering a building: through membrane fusion or endocytosis.
Leaving the mailroom: escaping the endosome or completing intracellular trafficking.
Arriving at the office: Entering the cell nucleus or the cellular region where action is required.
Open the package: Uncoating complete, releasing genetic material.
Execution instructions: Utilize the molecular machinery of the host cell to express viral genes.
Viruses make people sick not usually because of the "delivery" itself, but because they deliver the virus's own genes, which then use cells to replicate in large numbers, destroy tissues, or trigger a strong immune response.
The basic engineering concept of Gene Therapy is:
Preserve the virus's most efficient delivery capabilities, remove unnecessary replication and pathogenic functions, and replace them with a therapeutic cargo.
Basic structure of a virus
Most viruses have two core structures.
Viral genome
It could be DNA or RNA, or it could be single-stranded or double-stranded.
It stores the information needed for virus replication and assembly.
Capsid
The capsid is a protein shell used to protect the viral genome.
Capsid is more than just packaging.
It will also have the following effects:
Cell attachment
Receptor interaction
Tissue tropism
Intracellular trafficking
Antibody recognition
Genome packaging
Capsid stability
Some viruses also have a lipid envelope, such as influenza virus and coronavirus.
AAV, on the other hand, is a small, single-stranded DNA virus without an envelope.
Why choose AAV?
AAV stands for Adeno-associated virus.
It was initially discovered in adenovirus samples, and because wild-type AAVs typically require the functionality provided by helper viruses to effectively perform productive replication, it was classified as dependoparvovirus.
AAV has become an important gene therapy platform for several reasons:
There is currently no clear evidence that naturally occurring AAV causes specific human diseases.
Tissue distribution can be adjusted by using the capsid and the method of drug delivery.
Relatively durable transgene expression can be established in many inactive dividing cells.
Recombinant AAV removes most of the original viral genes and does not have the full functionality required for self-replication.
We have accumulated extensive experience in clinical trials and product approvals.
However, it must be clarified here:
AAVs are often referred to as "non-integrating vectors," but a more accurate description would be recombinant AAVs. In most cases, they exist primarily in episomal forms, with a relatively low frequency of genomic integration, though it is not absolutely impossible. AAV integration and long-term safety remain topics of ongoing research and monitoring. ( PubMed )
If this is your first time encountering Gene Therapy, reading this far should be enough to understand most of the basic concepts of AAV news.
Next, we will delve into AAV vector design, capsid biology, manufacturing, CMC, and clinical safety.
Part II | Advanced AAV Biology: An Advanced Introduction for Researchers and Industry Professionals
Wild-type AAV genome: A very small but highly concentrated viral genome.
The wild-type AAV genome is approximately 4.7 kb and is a single-stranded DNA genome.
The core structure includes:
Inverted terminal repeats at both ends, abbreviated as ITRs
rep gene
cap gene
ITR consists of approximately 145 bases and can form special hairpin structures that participate in genome replication, rescue, and packaging.
The Rep region produces various replication proteins, such as Rep78, Rep68, Rep52, and Rep40, which participate in genome replication and packaging.
The Cap region then produces structural proteins such as VP1, VP2, and VP3, forming the AAV capsid. ( Addgene )
AAV capsid: More than just a packaging shell
AAV capsid is a protein shell with icosahedral symmetry.
Each capsid consists of approximately 60 VP subunits, primarily VP1, VP2, and VP3. Traditionally, they are often described in a ratio close to 1:1:10, but the actual composition can be influenced by serotype, production system, and assembly process, and is not necessarily a completely fixed ratio. ( Nature )
VP3 forms the main structure of the capsid shell.
The N-terminal extensions of VP1 and VP2 are related to processes such as intracellular trafficking, endosomal escape, and nuclear entry.
Specific amino acid residues on the capsid surface also have an effect:
Receptor binding
Cell attachment
Antibody recognition
Tissue distribution
Intracellular trafficking
Uncoating
Manufacturing yield
Capsid stability
Therefore, capsid engineering is not just about adjusting "which organ it goes to".
A new capsid must balance many properties simultaneously:
Is it possible to produce it?
Can it be assembled correctly?
Can the genome be loaded effectively?
Is it stable in the blood?
Is it easily recognized by antibodies?
Can it enter the target cell?
Is it possible to successfully carry out intracellular trafficking?
Will it accumulate in non-target organs?
Does this create new immune or toxic risks?
This is why engineered capsid, which performs well in mice, may not necessarily be directly converted to nonhuman primate, let alone be successful in humans.
How was the Recombinant AAV redesigned?
In therapeutic recombinant AAVs, the original rep and cap coding sequences of wild-type AAVs are usually removed from the vector genome.
Instead, an expression cassette is used, which typically includes:
Promoter
Enhancer
Therapeutic transgene
Intron, add as needed for design.
Polyadenylation signal
Other regulatory elements
This expression cassette is still flanking at both ends of the ITR.
During production, rep, cap, and helper functions are provided by other plasmids or production components via trans. In other words, these production-required genes assist cells in assembling the vector, but should not be the primary content of the final therapeutic vector genome.
Common transient triple transfection systems typically include:
Vector plasmid
Contains ITR-flanked therapeutic expression cassette.
Rep/Cap plasmid
Provides AAV replication proteins and specified capsid proteins.
Helper plasmid
It provides functionality that was originally provided by helper viruses such as adenovirus.
This design allows recombinant AAVs to carry therapeutic genes, but it loses the complete genetic machinery needed to replicate itself and form the next generation of viruses.
From the extracellular space to the nucleus: AAV transduction is not just about "entering the cell".
AAV transduction is the sum of a series of steps.
It generally includes:
Interact with cell surface attachment factors or receptors.
It enters the cell via endocytosis.
Trafficking is performed in the endosomal system.
To avoid being sent to lysosomal degradation.
Capsid produces configurational changes.
Complete the endosomal escape.
Move to the vicinity of the cell nucleus.
It enters the cell nucleus.
Uncoating and releasing the vector genome.
Single-stranded genome through second-strand synthesis, or with complementary strand annealing.
This leads to the formation of more stable episomal DNA structures.
Initiate transgene transcription and protein expression.
Every step can become a bottleneck to efficiency.
Therefore, when a capsid performs poorly in a cell, it's not necessarily because it's completely unable to enter the cell; it could also be because:
Unable to effectively escape endosome
Insufficient nuclear transport efficiency
Uncoating is too slow
Poor Genome Conversion
Promoter is inactive in this cell.
Transgene mRNA or protein is unstable.
This is why, when evaluating AAV vectors, one cannot only look at the total tissue vector genome copy number.
The presence of DNA in tissues does not necessarily mean the production of therapeutically significant protein expressions.
Serotype and tissue tropism: not a fixed, unchanging map of organs
Different AAV capsids have different biodistribution and cell transduction profiles.
Common examples include:
AAV capsid/serotype | Common research or application directions | Representative Cases |
AAV2 | Retina, CNS local delivery | Luxturna, Upstaza |
AAV5 | Liver-directed delivery | Hemgenix |
AAV8-related capsids | Liver, some muscle applications | Multiple liver-directed programs |
AAV9 | CNS,muscle,systemic delivery | Zolgensma |
AAVrh74 | Skeletal muscle-directed systemic delivery | Elevidys |
However, this table can only be used as a starting point for simplification.
Tissue tropism is not determined solely by capsid.
Actual performance is also affected by the following factors:
Species difference
Route of administration
Dose
Age
Disease state
Vascular permeability
Pre-existing immunity
Receptor abundance
Promoter specificity
Vector genome design
Manufacturing attributes
Assay used to define transduction
For example, some AAV9-based vectors can show a wide CNS distribution in animal models, but the extent to which they cross the blood-brain barrier is species-, age-, and dose-dependent, and cannot be simplified to "AAV9 can definitely cross everyone's BBB effectively".
Promoter engineering: Reaching the organ does not equate to expression in the correct cells.
Capsid determines which tissues and cells the vector can reach, but promoters and other regulatory elements further determine where the transgene is expressed, how much it is expressed, and how long it is maintained.
Common promoter types include:
CMV
CAG
EF1α
Liver-specific promoters
Muscle-specific promoters
Neuron-specific promoters
Cell type-specific synthetic promoters
Choosing the promoter with the highest strength is not necessarily the best design.
Excessive transgene expression may cause:
Protein misfolding
ER stress
Cellular toxicity
Unwanted expression in off-target cells
Increased antigen presentation
Stronger immune recognition
Conversely, a promoter that is too weak may not be able to reach the therapeutic threshold.
Therefore, the core of expression cassette optimization is not to pursue maximum performance, but to establish an appropriate therapeutic window.
Payload limitation: Why can AAV only carry about 4.7 kb?
AAV's natural genome is only about 4.7 kb, and the space for the capsid is also quite limited.
Therapeutic payloads include not only the coding sequence, but also:
ITRs
Promoter
Regulatory elements
Transgene coding sequence
Polyadenylation signal
When the vector genome exceeds the reasonable packaging range, the following may occur:
Packaging efficiency decreased
Genome truncation
Heterogeneous packaged genomes
Reduced full-length genome proportion
Lower potency
Product characterization is more complex
Recent genome packaging analyses also show that the proportion of full-length packaged genomes may decrease rapidly when the vector genome approaches approximately 4.9–5.0 kb. ( ScienceDirect )
Why does Elevidys use micro-dystrophin?
Duchenne muscular dystrophy is caused by a DMD gene mutation.
The full-length dystrophin coding sequence is too large, far exceeding the normal capacity of a single AAV vector.
Therefore, instead of stuffing the complete dystrophin gene into AAV, the researchers designed a shortened version called micro-dystrophin.
Micro-dystrophin retains some domains that are considered important for muscle cell structure and function, while removing some unnecessary regions, allowing the coding sequence to be placed into the AAV expression cassette.
This is an engineering compromise:
It is not a full-length dystrophin.
It does not mean that the muscles can be fully restored to normal.
The goal is to produce functional proteins that can alter the progression of disease.
Therefore, when evaluating this type of therapy, it is not enough to simply ask "whether micro-dystrophin is present"; it is also necessary to ask further questions:
Which muscles are involved?
How many muscle fibers are visible?
Is the protein localization correct?
Is the amount of performance sufficient?
Can it be transformed into a lasting functional benefit?
How long can the effects last as the patient grows and the disease progresses?
Self-complementary AAV: Expressing speed using load swapping
After a traditional single-stranded AAV enters a cell, it needs to complete second-strand synthesis or complementary strand annealing in order to form a double-stranded template suitable for transcription.
Self-complementary AAV, or scAAV for short, encapsulates a genome with self-complementary properties, enabling it to form double-stranded DNA more quickly, which can typically accelerate transgene expression.
However, the cost is a further reduction in available payload capacity, approximately half that of traditional AAV.
Therefore, scAAV is suitable for smaller transgenes, but not for all diseases.
This once again demonstrates that AAV engineering is essentially a series of trade-offs.
Solutions for large genes: Dual AAV and other segmentation strategies
For genes that exceed the capacity of a single AAV, a dual-vector strategy can be considered.
The therapeutic gene is divided into two parts, each loaded into two AAV vectors, and then, after entering the same cell, it is expected to be processed through:
Homologous recombination
Trans-splicing
Hybrid approaches
Protein trans-splicing
To rebuild a complete or nearly complete product.
However, dual AAV also brings new problems:
The same cell must receive two vectors at the same time.
Reconstitution efficiency may be insufficient.
The product dosage and manufacturing complexity have increased.
Incomplete or abnormal intermediate products may be produced.
Analytical characterization is even more difficult.
Therefore, dual AAV is not simply a matter of mixing two vectors together, but a completely new product design problem.
AAV Manufacturing: How is a gene therapy drug made?
Many people see that AAV has a small structure and intuitively think that it should be easy to manufacture.
In fact, AAV is one of the most complex biologics manufacturing products currently available.
One of the most widely used production methods is transient triple-plasmid transfection in HEK293 cells. Other methods include producer cell lines, baculovirus/Sf9, and other production systems.
Triple transfection is highly flexible, allowing for relatively quick replacement of capsids and transgene cassettes, making it suitable for different product development.
But it also faces:
High demand for GMP-grade plasmids
Transfection consistency
Scale-up complexity
Batch-to-batch variability
Control of cell density and transfection timing
The effect of plasmid ratio and reagent mixing
Yield and product quality are unstable.
Triple transfection remains a widely used rAAV production method, but low yield, full-to-empty ratio, and process reproducibility continue to be significant challenges. ( ScienceDirect )
AAV downstream process: transforming cell culture medium into a drug.
After AAV production is completed, the cell culture medium is not directly loaded into the vial.
A typical process may include:
Cell harvest or culture supernatant collection
Cell lysis depends on the vector and process.
Nuclease treatment
Clarification
Concentration and buffer exchange
Affinity chromatography
Ion-exchange chromatography
Empty/full capsid enrichment
Additional polishing
Sterile filtration
Formulation
Fill and finish
Each step can cause vector loss, aggregation, or potency change.
Different capsids have different surface properties, and the same purification process may not be directly applicable to another serotype or engineered capsid.
This is why platform manufacturing is so attractive, yet so difficult in practice.
Empty, partial, and full capsid: Why are these important CMC issues?
During the production process, not every capsid will successfully contain a complete therapeutic genome.
The final product may include:
Full capsids
Empty capsids
Partially filled capsids
Capsids containing truncated genomes
Capsids containing unintended DNA fragments
Aggregates
Degraded particles
Full capsid typically refers to a vector particle containing the expected therapeutic genome.
An empty capsid has a capsid shell, but does not contain a complete vector genome.
Partial capsids may contain incomplete or abnormal DNA.
The actual impact of these capsid populations varies by product, but empty and intermediate capsids are generally considered product-related impurities that need to be controlled because they may increase unwanted capsid antigen burden and may also affect product consistency and potency interpretation. ( Nature )
However, this does not mean that all products must achieve the exact same full capsid percentage.
The real CMC problem is:
Can the manufacturing process be kept under stable control?
Is the analytical method accurate?
Does the specification have clinical and process support?
Will different capsid populations change safety or efficiency?
Does batch comparability hold true?
AAV Quality Control: It doesn't end once the vector genome titer is detected.
AAV quality analysis typically needs to cover identity, purity, quantity, potency, and safety.
Common items include:
Vector genome titer
Vector genome concentration is often measured using qPCR or ddPCR.
However, qPCR/ddPCR detects DNA targets, which does not necessarily mean that every genome is intact, nor does it mean that every particle is biologically active.
Capsid titer
Capsid concentration can be assessed using ELISA, mass-based methods, or other analytical methods.
Full-to-empty ratio
Possible uses:
Analytical ultracentrifugation
Charge-detection mass spectrometry
Mass photometry
Cryo-EM
Chromatographic methods
Other orthogonal approaches
Different methods have different measurement principles, and the results are not necessarily completely the same.
Genome integrity
It can be used for:
Restriction analysis
Southern blot
Next-generation sequencing
Long-read sequencing
Other molecular assays
Confirm that the DNA loaded into the capsid is the expected full-length genome.
Purity and impurities
include:
Host-cell protein
Host-cell DNA
Residual plasmid DNA
Residual nuclease
Residual process reagents
Aggregates
Replication-competent AAV risk
Microbial and endotoxin testing
Potency assay
Potency assays must reflect the product's mechanism of action as accurately as possible.
Depending on the product, the following measurements may be required:
Cell entry
Transgene expression
Protein activity
Downstream biological response
Functional rescue
An assay that only measures transgene mRNA or protein quantity may not be sufficient to describe the complete potency.
Therefore, establishing a potency assay that can be linked to a clinical mechanism and has sufficient precision and robustness is often one of the most difficult tasks in AAV CMC.
Clinical applications of AAV
Luxturna: A significant milestone in localized ophthalmic gene therapy
Luxturna is an AAV vector-based gene therapy for confirmed biased RPE65 mutation-associated retinal dystrophy.
Patients must also maintain a sufficient number of viable retinal cells, as gene delivery requires target cells that are still alive, can accept the vector, and express RPE65. ( US Food and Drug Administration )
Luxturna's importance lies not only in its approval as a product, but also in its demonstration that, with appropriate disease, local administration, and a clear genetic diagnosis, AAVs can be transformed into clinically significant treatments.
The eye is a relatively localized organ environment that can be directly delivered and uses low-dose treatments, which is very different from DMD, which requires high-dose treatment of a large number of muscles throughout the body.
Zolgensma: Treatment of SMA using whole-body delivery
Zolgensma uses an AAV-based vector to provide a functional SMN1 transgene for specific SMA children under two years of age. ( US Food and Drug Administration )
This therapy shows that AAV has the potential to alter the natural course of serious genetic diseases with a single treatment.
But it also illustrates the importance of timing in treatment.
Gene therapy can supplement the function of missing genes, but it cannot necessarily completely reverse lost neurons. Therefore, newborn screening, early diagnosis, and early treatment may directly affect the final treatment outcome.
Hemgenix and Roctavian: Turning the Liver into a Factory for Clotting Factors
Hemgenix is used in certain adult patients with Hemophilia B to induce Factor IX expression in liver cells. ( US Food and Drug Administration )
Roctavian is an AAV-based gene therapy used in certain adult patients with severe Hemophilia A to induce Factor VIII expression in liver cells. ( US Food and Drug Administration )
Hemophilia is a very reasonable application of liver-directed AAV gene therapy because:
The target protein can be produced by liver cells and secreted into the bloodstream.
It is not necessary to transduce every cell in the body.
Even if the restored clotting factor activity does not reach the level of a normal person, it may still significantly reduce the risk of bleeding.
However, hemophilia gene therapy also reveals the complexity of durability.
Transgene expression may decrease over time in some patients, and there may be significant differences in the amount of expression, immune response, and duration between different patients.
"One treatment" does not necessarily mean "all patients will maintain the same therapeutic effect for life".
Upstaza: Directly delivers AAV2 to specific areas of the brain.
Upstaza is a gene therapy for aromatic L-amino acid decarboxylase deficiency.
It uses a non-replicating recombinant AAV2 vector carrying the human DDC gene and delivers the treatment to a specific location in the brain via intraputaminal administration. ( European Medicines Agency (EMA) )
This case highlights the value of the route of administration.
When systematic delivery fails to effectively reach the target area or causes excessive exposure of non-target areas, localized, image-guided precision delivery may become a more reasonable strategy.
Elevidys: Breakthroughs and Controversies in DMD Gene Therapy
Elevidys is a DMD gene therapy that uses AAVrh74 capsid to deliver micro-dystrophin expression cassette.
As of now, the FDA's product page indicates that Elevidys is indicated only for patients aged four years and older who are still able to walk and have a confirmed DMD gene mutation. ( US Food and Drug Administration )
This therapy is of great importance.
DMD affects a large number of skeletal muscles throughout the body, and patients require a much higher vector dose than local ophthalmic gene therapy.
This also makes Elevidys an important case study for understanding systemic high-dose AAV risk.
Elevidys security incident: What do we really need to understand?
Elevidys first received accelerated approval from the FDA in 2023, and its indications have since been expanded.
However, in 2025, a security incident changed the product's risk assessment.
In June 2025, the FDA announced that two non-ambulatory pediatric male DMD patients who received Elevidys developed fatal acute liver failure after treatment. ( US Food and Drug Administration )
In July 2025, the FDA stated that as of July 18, it had received three reports of fatal acute liver failure following the use of Sarepta AAVrh74 gene therapies; however, not all of these cases fell under the approved use scenarios for Elevidys products. ( US Food and Drug Administration )
In November 2025, the FDA approved a new boxed warning and limited the indication for Elevidys to patients with DMD who were still able to walk. ( US Food and Drug Administration )
Therefore, the original simplification of the incident as "the third eight-year-old child was later determined to be unrelated to Elevidys, so the drug supply was resumed" is incomplete and no longer in line with subsequent regulatory developments.
The most accurate conclusion at present is:
The indications for Elevidys have been narrowed.
Acute serious liver injury and acute liver failure are the core risks associated with boxed warnings.
The risk-benefit assessment of the non-ambulatory population has undergone a substantial change.
The monitoring and patient selection for AAV systemic therapy must be more stringent.
Does the Elevidys incident signify the failure of the AAV platform?
I don't think it should be simplified like that.
The Elevidys incident does not reflect the idea that "all AAVs are equally dangerous," but rather the result of several risk factors combined:
Intravenous administration
Very high vector dose
A large number of skeletal muscle targets
The liver may still be subjected to significant vector exposure.
The patient's own disease condition
Capsid-specific and transgene-related immune responses
Age, walking condition, and differences in existing organ function
Are corticosteroids or other immunomodulations sufficient?
Localized, low-dose ophthalmic AAVs and high-dose systemic muscle-directed AAVs should not be considered the same safety scenario simply because they are both called AAVs.
A more precise question would be:
Is the benefit-risk profile acceptable for this disease, this patient population, this capsid, this expression cassette, this dosage, and this administration route?
Key Security Challenges of AAV
Pre-existing neutralizing antibodies
Many people have been exposed to naturally occurring AAV in the past, so they may already have neutralizing antibodies in their bodies.
Even if the antibody concentration is not high, it may bind to vector capsid, reduce tissue transduction, or accelerate vector clearance.
Therefore, many clinical trials screen for anti-AAV antibodies before treatment.
However, there is no completely consistent standard between different essays, serotypes, and cutoffs.
Repeat dosing
After the first AAV treatment, the immune system usually produces a stronger antibody response to capsid.
Therefore, reusing the same or similar capsid may quickly lead to neutralization.
This is one of the biggest differences between AAV and some non-viral delivery systems.
The research strategy of repeating dosing includes:
Use different capsids
Plasmapheresis
Antibody-degrading enzymes
B-cell or plasma-cell modulation
Transient immune suppression
Capsid immune evasion
Local delivery
Lower dosage, higher efficiency vector
However, each method introduces new safety, manufacturing, or regulatory problems.
Hepatotoxicity
Even if the treatment target is not the liver, systemically administered AAV often still results in a significant portion reaching the liver.
Hepatotoxicity may involve:
Innate immune activation
Adaptive immune response
Capsid antigen presentation
Transgene expression
Dose-related cellular burden
Complement and inflammatory pathways
Patient-specific susceptibility
Hepatotoxicity is one of the most common and concerning adverse reactions in AAV gene therapy; severe hepatotoxicity and fatal liver failure have also been observed in high-dose studies. ( PubMed )
Complement activation, thrombocytopenia and thrombotic microangiopathy
High doses of systemic AAV may induce complement activation, accompanied by:
Thrombocytopenia
Hemolysis
Renal injury
Endothelial injury
Thrombotic microangiopathy-like syndrome
These reactions can develop rapidly, so early monitoring after treatment is very important.
Cellular immune response
Capsid peptides or transgene-derived peptides may be recognized by T cells via MHC presentation.
This may lead to:
Transduced cells were cleared
Transgene expression decreased
Tissue inflammation
Loss of efficacy
Organ-specific toxicity
Corticosteroids are frequently used to manage immune responses, but not all responses can be completely controlled by steroids alone, especially at very high systemic vector doses. ( Frontiers )
Dorsal root ganglion toxicity
In some intrathecal, intra-CSF, or high-dose AAV animal studies, pathological changes in dorsal root ganglion sensory neurons have been observed.
The current relevant mechanisms may involve:
Excessive transgene expression
RNA toxicity
Cellular stress
Immune-mediated injury
The interaction between Capsid, cargo, dose, and delivery route
DRG findings are more common in nonhuman primate studies, but clinical manifestations and human risks still need to be assessed on a product-by-product basis. Related studies also indicate that immune responses may play a causal role in some DRG pathologies. ( ScienceDirect )
What should be monitored after AAV treatment?
The protocols differ between products, but may include:
ALT, AST, bilirubin
Albumin
Prothrombin time or INR
Platelet count
Creatinine and renal function
Complement markers
Troponin, depending on the product and risk.
Creatine kinase
Cytokines
Anti-capsid antibodies
T-cell responses
Transgene protein level
Vector shedding
Clinical functional outcomes
Long-term follow-up is also very important, because the effects and potential risks of a one-time Gene Therapy may last for many years.
For example, Upstaza's risk management program includes at least ten years of post-treatment registry follow-up. ( European Medicines Agency (EMA) )
Next-generation AAV: What problems are researchers solving?
Capsid engineering
In the past, we often started with natural serotypes.
More and more teams are now using it:
Directed evolution
Rational design
DNA shuffling
Peptide insertion libraries
Barcoded screening
In vivo selection
Human tissue models
Machine learning
Generative protein design
Looking for capsids with better properties.
The ideal new capsid not only needs to improve transduction, but also needs to improve:
Tissue specificity
Human translation
Immune evasion
Manufacturing yield
Genome packaging
Stability
Lower liver exposure
Lower effective dose
The real difficulty is that these properties do not necessarily improve at the same time.
Increasing organ tropism may decrease production yield; altering antibody epitope may affect receptor binding; increasing potency may also increase off-target expression.
Therefore, the next generation of capsid engineering is multi-objective optimization, rather than just looking for a single highest signal.
Achieve the same therapeutic effect with a lower dosage.
As seen in Elevidys and other systemic AAV programs, one of the most valuable advancements in the future is not enabling vectors to use higher doses, but rather reducing the doses required to achieve the same therapeutic effect.
Lowering diet may also improve:
Manufacturing burden
Treatment cost
Capsid antigen exposure
Liver exposure
Complement activation
Repeat doing feasibility
Overall therapeutic window
Therefore, capsid, promoter, transgene, route of administration, and patient selection must all be optimized together.
More precise expression control
Future vector designs will not simply involve replacing the promoter with a tissue-specific promoter.
Also possible additions:
Cell-selective enhancers
microRNA target sites
Inducible expression systems
Detargeting elements
Post-transcriptional regulation
Protein degradation control
Transgene activity switches
For example, adding specific microRNA target sequences to cells where transgene expression is not desired may reduce off-target expression.
This type of design will allow Gene Therapy to gradually move from "delivering to organs" to "acting only in the right cells at the right dosage".
Immune evasion and redosing
For next-generation AAVs to be extended to more common diseases, repeat dosing will be an important issue.
Possible routes of immune escape include:
Capsid epitope engineering
Antibody-resistant capsids
Transient immune modulation
Enzymatic antibody depletion
Alternative route of administration
Shielding strategies
Sequential use of orthogonal capsids
However, the immune system is not just about neutralizing antibodies.
Even if you avoid the enemy, you still need to consider:
Innate sensing
Complement
T-cell response
Transgene immunity
Patient infection history
Immunosuppressive treatment risk
Therefore, "immune-evasive capsid" is not a problem that can be completely solved by a single mutation.
AAV, LNP, Lentivirus, and VLP: Which will become the next-generation Gene Therapy platform?
I don't think these platforms are only in competition with each other.
They are more like tools for different purposes.
Platform | More suitable applications | Key advantages | Main challenges |
AAV | In vivo, long-term protein performance | With mature clinical experience, it can perform well in a variety of tissues over a long period of time. | Small payload, immune response, redosing difficulties |
Lentivirus | Ex vivo cell therapy, HSC engineering | Stable integration, large load capacity | Insertional risk, complex manufacturing process and cell manipulation |
LNP | mRNA, siRNA, gene editing cargo | Modular manufacturing process, capable of delivering multiple RNAs, and has the potential for repeated drug delivery. | Extrahepatic targeting and cell specificity still need improvement. |
VLP | Transient delivery of gene-editing proteins or RNPs | Editing tools can be sent briefly, reducing long-term performance issues. | Clinical and manufacturing platforms are still in a relatively early stage. |
Adenovirus | Vaccine, oncolytic applications | Larger payload and stronger performance | High immunogenicity |
HSV-based vector | CNS, oncolytic therapy, large cargo | Large payload capacity, with potential for neurological applications. | Vector biology and manufacturing are more complex |
AAV is suitable for diseases that require long-term efficacy and where therapeutic genes can be incorporated into a limited payload.
LNPs are more suitable for applications that require short-term efficacy, repeatable administration, or delivery of mRNA and editing machinery.
Lentivirus still has irreplaceable value in ex vivo cell therapy.
The real important question is not:
Which platform is the best?
Instead:
Which delivery strategy is most appropriate for this disease, target cells, treatment mechanisms, and patient population?
Why can AAV Gene Therapy cost millions of dollars per session?
The high price of AAV Gene Therapy cannot be explained simply by "the company wants to make money" or "it's expensive to manufacture".
Costs and pricing are typically influenced by a number of factors simultaneously:
The number of patients is very small
Early research had a high failure rate
Long-term preclinical and clinical development
GMP plasmid and viral vector manufacturing
Low yield and high purification loss
Complex analytical testing
Long-term follow-up
Cold-chain logistics
Specialized treatment centers and inpatient monitoring
Payment model for one-time treatment
Sunk costs of developing unsuccessful programs
However, high development costs do not mean that any price is naturally reasonable.
When a single treatment costs millions of dollars, insurance companies, governments, and the healthcare system must rethink their approach:
Do you want to pay in one lump sum or in installments?
If the therapeutic effect is not maintained, should there be an outcome-based payment?
Which patients are most likely to benefit?
How long should long-term efficacy evidence be tracked?
How do small countries or single-insurance systems manage financial risk?
Can patients from other countries receive treatment?
Will prices reflect the decrease in manufacturing costs?
If gene therapy is to move from a few rare diseases to more widespread medical applications, the issues of payment and accessibility are no less important than those of capsid engineering.
LuTra Studio Insight: AAV has proven the feasibility of gene therapy, but it is also beginning to encounter the limitations of first-generation platforms.
Looking back at the development of AAV Gene Therapy over the past decade, I believe it has accomplished a very important task:
This proves that delivering therapeutic genes directly into the human body can truly alter the natural course of genetic diseases.
Luxturna, Zolgensma, Hemgenix, Roctavian, Upstaza, and Elevidys show us the potential of gene therapy in different organs such as the eyes, nervous system, liver, and muscles.
However, these products also made the limitations of the first-generation AAV platform even clearer.
When treatment shifts from localized, low-dose ophthalmic diseases to neuromuscular diseases requiring systemic, extensive transduction, capsid burden, liver exposure, immune response, and manufacturing demand all increase rapidly.
Therefore, I believe the next stage of competition in AAV will not simply be:
Who will find more genes that can be treated?
And it will gradually turn towards:
Who can deliver cargo more precisely to the right cells with lower doses, while reducing exposure to non-target organs and immune responses?
This is why engineered capsid, AI-assisted protein design, cell-specific promoter, immune modulation, and next-generation manufacturing will be the core technologies of the next decade.
I don't believe AAV will be completely replaced by LNP.
AAV excels at long-term DNA expression; LNP excels at shorter-term RNA delivery; Lentivirus is suitable for ex vivo stable cell engineering; VLP may find its place in transient gene editing delivery.
The future will not be a platform that governs all diseases.
Instead, different delivery technologies form a more precise division of labor based on disease mechanisms, target organs, treatment time, and safety requirements.
Conclusion: The next breakthrough for Gene Therapy still depends on delivery.
The development of genomics has helped us identify a large number of disease-related genes.
However, knowing which gene is malfunctioning does not mean we know how to treat it.
The truly difficult work remains:
Delivering treatment to the correct organ
Enter the correct cell
Producing the correct dosage of protein
To maintain a sufficiently long therapeutic effect
Avoid unacceptable immune and toxic risks
Establish scalable, controllable, and affordable processes.
AAV has brought Gene Therapy from concept to clinical application.
However, Elevidys and other high-dose systemic programs also remind us that AAV is not a delivery system without limits.
The true value of scientific progress lies not only in emphasizing success, nor in negating the entire platform because of security incidents.
More importantly, we can learn from each success and failure to understand the relationship between vector, cargo, patient biology, manufacturing, and immune system.
Only when basic science, engineering design, clinical development, CMC, and regulation advance in tandem can Gene Therapy gradually evolve from a breakthrough treatment for a small number of patients into a more mature, safer, and more accessible medical option.
References
High KA, Roncarolo MG. Gene Therapy. New England Journal of Medicine . 2019.
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery . 2019.
Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduction and Targeted Therapy . 2024.
Russell S, et al. Efficacy and safety of voretigene neparvovec in patients with RPE65-mediated inherited retinal dystrophy. The Lancet . 2017.
Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine .
Pasi KJ, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. New England Journal of Medicine .
FDA. Approved Cellular and Gene Therapy Products.
FDA. Luxturna product information.
FDA. Zolgensma product information.
FDA. Hemgenix product information.
FDA. Roctavian product information.
FDA. Elevidys product information and 2025 safety communications.
European Medicines Agency. Upstaza EPAR and product information.
Ronzitti G, Gross DA, Mingozzi F. Human immune responses to adeno-associated virus vectors. Frontiers in Immunology and related literature.
Recent literature on AAV manufacturing, capsid characterization, full/empty particle analysis and genome integrity.
Comments